Clearstone Reporting HbA1c Result Values in IFCC and NGSP Units for All Clinical Trials Globally
Clearstone Central Laboratories announced the company is reporting HbA1c result values in International Federation of Clinical Chemistry (IFCC) units as well as the National Glycohemoglobin Standardization Program (NGSP) standard units.
“Worldwide, many countries including most European countries, Japan and Australia have decided to change to IFCC units with a transition period of dual reporting” said Patrice Hugo, PhD, Clearstone’s Chief Scientific Officer. “We have been watching this issue very closely to advise our clients, and are pleased to offer the availability of both measurements for all studies through APOLLO CLPM™, our proprietary central laboratory protocol management system”.
As a result of having two reference standards for the measurement of HbA1c, Clearstone has made both reporting formats available to clients: IFCC (mmol/mol) and derived NGSP units (%). The correlation between these two is well documented, has been stable and is described by a robust equation: IFCC = (10.93 x NGSP) - 23.50. With this IFCC/NGSP master equation, all laboratories can provide derived units in either format. As recommended by the American Diabetes Association (ADA), Clearstone will continue to use an HbA1c threshold of 6.4% (46 mmol/mol) as the upper limit of normal.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
